Health Care • Biotechnology: Pharmaceutical Preparations
$24.03 ▲ +0.80
(+3.44%)
MKT CAP: $782.3M • VOL: 656.5K
52W L $21 52W H $51
COLL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $780.6M | $631.4M | $566.8M |
| YoY Revenue Growth % | +23.6% | +11.4% | — |
| Gross Profit | $463.3M | $377.3M | — |
| Gross Margin % | 59.3% | 59.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $179.6M | $169.9M | $167.0M |
| Operating Margin % | 23.0% | 26.9% | 29.5% |
| Net Income (GAAP) | $63.0M | $69.0M | $48.0M |
| EBITDA (Normalized) | $181.0M | $171.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $329.3M | $205.0M | $274.7M |
| Capital Expenditures (CapEx) | $1.7M | $1.7M | — |
| Free Cash Flow (FCF) | $327.6M | $203.3M | $274.7M |
| FCF Margin % | 42.0% | 32.2% | 48.5% |
| Return on Invested Capital (ROIC %) | 95.0% | 84.8% | — |
| Cash & Short-Term Equivalents | $231.3M | $70.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $301.7M | $228.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COLL.